An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide not only saw stronger improvements in blood sugar and weight ...
Mar 30, 2026
0
2
Popular GLP-1 receptor agonist drugs for weight loss, also known as GLP-1 RAs, appear to be similarly effective among patients of different ages, races, and starting weights, with women benefiting somewhat more than men, ...
Mar 4, 2026
0
10
Popular weight-loss drugs, including Ozempic, Wegovy, Trulicity and Mounjaro, produced by independent pharmacy labs, sickened some 8,000 or more Marylanders a year by 2024. The Food and Drug Administration has announced that ...
Feb 24, 2026
0
17
Fifteen prescription medications, including Botox and the diabetes drug Trulicity, will be the focus of federal price negotiations that could lower prices for Medicare patients.
Jan 29, 2026
0
8
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according ...
Dec 30, 2025
0
16
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the medications have similar ...
Nov 3, 2025
0
24
Ecnoglutide, a novel once-weekly injection for type 2 diabetes management, works as well as dulaglutide (a commonly prescribed once-a-week injection to manage diabetes) in lowering blood sugar levels, confirms a phase 3 randomized ...
Aug 25, 2025
0
22
People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to those who take weekly injections of GLP-1 anti-obesity medications, according to a new study presented ...
Jun 17, 2025
0
13
Type 2 diabetes patients taking semaglutide, often sold as Ozempic or Wegovy, have a slightly lower risk of stroke compared to patients taking another diabetes drug—empagliflozin. International researchers studied data from ...
Jun 17, 2025
0
24
For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with escalating treatment with ...
Apr 4, 2025
0
22
